Results 141 to 150 of about 40,902 (256)

Spironolactone therapy in resistant hypertension comorbid with mild obstructive sleep apnea: A retrospective cohort study. [PDF]

Medicine (Baltimore)
Fang C, Ma B, Xiao N, Zhao H, Ren S.
europepmc   +1 more source

Traditional Chinese Medicine and Natural Products Targeting Right Ventricular Dysfunction in Pulmonary Arterial Hypertension: Toward Precision Cardiometabolic Therapy

iNew Medicine, EarlyView.
Natural products and traditional Chinese medicine target metabolic pathways underlying right ventricular dysfunction in pulmonary arterial hypertension. Integrating multi‐omics, artificial intelligence, and systems biology may enable precision cardiometabolic therapies to restore right ventricular metabolism and improve clinical outcomes.
Yihao Wu, Zhehui Tang, Hongwei Yao
wiley   +1 more source

Distal radial artery access for renal denervation in resistant hypertension: a case report. [PDF]

Eur Heart J Case Rep
Zhao Y, Du Y, Tang Y, Yu M, Gao L.
europepmc   +1 more source

Hydrogel‐based drug delivery systems for intracerebral hemorrhage with therapeutic advances and emerging roles of the bone–brain axis

Interdisciplinary Medicine, EarlyView.
Hydrogel‐based drug delivery systems offer a promising approach for treating intracerebral hemorrhage (ICH) by overcoming blood‐brain barrier limitations, enabling precise, sustained release of neuroprotective and anti‐inflammatory agents. These systems enhance treatment efficacy, but challenges remain in biosafety, drug penetration, and scalability ...
Haojun Shi, Min Chen, Yisheng Chen, MengYao Li, Jiale Ma, Zuozhen Yin, Li Wu, YangBao Miao, Zemin Ou, Ke Wu, Zhijie Xu, Lizhi Li, Shaocong Zhao, Shiwei He, Bin Huang, Guanwen He, Guanghui Wu, John H. Zhang, Liang Shi   +18 more
wiley   +1 more source

Highlights of the 2026 Korean Society of Hypertension guidelines for the management of hypertension: what's new and what has changed. [PDF]

Clin Hypertens
Lee EM, Cho IJ, Kang HT, Kim KI, Kim DH, Kim JH, Kim HL, Kim HC, Kim HJ, Koh ES, Park S, Park JM, Shin JH, Lee J, Lee HY, Lee H, Jung MH, Cho EJ, Choi S, Ihm SH, Committee of Korean Society of Hypertension Guidelines for the Management of Hypertension.   +20 more
europepmc   +1 more source

S100A9 promotes pulmonary arterial hypertension by regulating mitochondria–endoplasmic reticulum interaction‐mediated inflammatory injury of endothelial cells

Interdisciplinary Medicine, EarlyView.
Macrophage‐derived S100 calcium‐binding protein A9 (S100A9) promotes the pathological progression of pulmonary arterial hypertension (PAH). S100A9 upregulates the interaction between signal‐transducing adaptor protein 2 and leucine‐rich repeat kinase 2, thereby regulating mitochondria–endoplasmic reticulum (ER) contact.
Chen Gong, Long Chen, Yiting Zhao, Xiaohe Wang, Qiang Yuan, Xiaofeng Fang, Liuyi Li, Yinbo Xu, Shumei Jiang, Guangwen Xu, Ke Meng, Delong Wang, Kangli Cao, Jianlong Sheng, Liling Guo, Shichun Shen   +15 more
wiley   +1 more source

Renal denervation revisited: is patient selection the missing link between failure and success? [PDF]

Clin Hypertens
Shahverdi E, Herda LR, Manouchehri R, Shahi S, Lange M.   +4 more
europepmc   +1 more source

A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside

Interdisciplinary Medicine, EarlyView.
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione, Ana Talamillo, Juan M. Falcón‐Pérez   +2 more
wiley   +1 more source

Clinical characteristics and vascular involvement of Takayasu arteritis versus Kawasaki disease in infants and young children. [PDF]

Pediatr Rheumatol Online J
Wang C, Xu Y, Lai J, Li X.
europepmc   +1 more source

[Diagnostics and treatment of resistant arterial hypertension].

Likars'ka sprava, 2003
Resistant arterial hypertension (RAH) is considered to be present in those cases where there is an increase in the arterial pressure (AP), if AP baseline level cannot be reduced down to 150/100 mm Hg and below that mark in conducting therapy with a triple-and-more drug regimens including diuretics and vasodilators prescribed in doses approaching the ...
openaire   +1 more source